According to a new report, published by KBV research, The Global Exosome Diagnostic and Therapeutic Market size is expected to reach $1.4 billion by 2028, rising at a market growth of 26.5% CAGR during the forecast period.
The Therapeutic segment is showcasing a CAGR of 28.7% during (2022 - 2028). This is due to a rise in the prevalence of chronic diseases and a surge in drug development demand. Exosomes, like COVID-19, have the potential to be used as a therapeutic platform for a variety of disorders. Exosomes offer practical potential in the treatment of a variety of diseases and tissue regeneration by delivering therapeutic cargo components while avoiding immune rejection and cellular damage. Exosomal treatment for respiratory viral infections, such as SARS-CoV-2, can also be developed using stemcell-derived exosomes, which are helpful in utilizing the anti-inflammatory and regenerative characteristics of parent cells.
The Reagent segment acquired maximum revenue share in the Global Exosome Diagnostic and Therapeutic Market by Product in 2021, thereby, achieving a market value of $655.1 million by 2028. The reagent segment acquired the largest revenue share in the exosome diagnostic and therapeutic market in 2021. This is due to an increase in the need for molecular diagnosis and an increase in diagnostic research and development. A reagent, often known as an analytical reagent, is a material or compound that is added to a system to initiate or test a chemical reaction. Although the terms reactant and reagent are frequently interchanged, reactant refers to a substance consumed during a chemical reaction.
The Diagnostic Center segment has shown growth rate of 27.5% during (2022 - 2028). This is related to the rise in chronic disease prevalence and the need for molecular diagnosis. Exosomes are extracellular vesicles with a diameter of 40-150 nm that are discharged by all cell types, including malignant cells. Exosomes are lipid bilayer members that are persistent in body fluids and often contain DNA, RNA, and proteins. Exosomes can be extracted from blood, plasma, serum, urine, or saliva and tested for tumor-related mutations. As a result, it provides an alternative to conventional tumor detection approaches
The North America is the fastest growing region in the Global Exosome Diagnostic and Therapeutic Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $542 million by 2028. The Asia Pacific market is estimated to witness a CAGR of 27.1% during (2022 - 2028). Additionally, The Europe market would experience a CAGR of 26.2% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/exosome-diagnostic-and-therapeutic-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Bio-Techne Corporation, Qiagen N.V., Thermo Fisher Scientific, Inc., Aethlon Medical, Inc., Capricor Therapeutics, Inc., Malvern Panalytical Ltd., NanoSomix, Inc., System Biosciences, LLC, and NX Pharmagen, Inc.
By Application
By Product
By End User
By Geography
Companies Profiled
Unique Offerings 
